<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801953</url>
  </required_header>
  <id_info>
    <org_study_id>2263/2020</org_study_id>
    <nct_id>NCT04801953</nct_id>
  </id_info>
  <brief_title>Nimodipine in Vestibular Schwanommas</brief_title>
  <official_title>Intraoperative Application of Nimodipine to the Facial and Cochlear Nerves During Vestibular Schwannoma Resection to Avoid Spasm-related Postoperative Facial Paralysis and Deafness - a Prospective Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title:&#xD;
&#xD;
      Intraoperative application of nimodipine to the facial and cochlear nerves during vestibular&#xD;
      schwannoma resection to avoid spasm-related postoperative facial paralysis and deafness - a&#xD;
      prospective randomized study&#xD;
&#xD;
      Background:&#xD;
&#xD;
      In patients undergoing microsurgical resection of a vestibular schwannoma, the facial and&#xD;
      vestibulocochlear nerves are at risk. Prior studies suggested positive effects of nimodipine&#xD;
      for preservation of the nerve function in these patients. A prospective, randomized, placebo&#xD;
      controlled double-blinded study will be conducted to evaluate the neuro-protective effect of&#xD;
      locally administered nimodipine during resection of vestibular schwannomas.&#xD;
&#xD;
      Investigational drug:&#xD;
&#xD;
      active group: &quot;Nimotop® 10mg - Infusionsflasche&quot; placebo: &quot;Natrium chloratum physiologicum&#xD;
      0,9% - Medica Infusionslösung&quot;&#xD;
&#xD;
      Rationale for the study: Nimodipine is supposed to counteract the vasoconstriction of&#xD;
      cerebral arteries caused by microsurgical manipulation and might thereby preserve facial and&#xD;
      cochlear nerve function&#xD;
&#xD;
      Aims of the study: Evaluation of the effect of intraoperative local administration of&#xD;
      nimodipine on the postoperative function of the facial and vestibulocochlear nerves after&#xD;
      microsurgical resection of vestibular schwannomas&#xD;
&#xD;
      Study design: prospective, double-blinded, single-center, randomized phase III trial&#xD;
&#xD;
      Study population: Patients undergoing microsurgical resection of a vestibularis schwannoma&#xD;
      with a maximum diameter of 10-25mm on MRI at the Department of Neurosurgery, Medical&#xD;
      university of Vienna.&#xD;
&#xD;
      Number of Patients: 30&#xD;
&#xD;
      Methods: In 15 patients, nimodipine will be administered locally to the facial and&#xD;
      vestibulocochlear nerves during resection of a vestibular schwannoma (= treatment group). In&#xD;
      another 15 patients, a placebo (sodium chloride solution) will be administered. In both&#xD;
      cases, a soaked gel foam pad will be used. The operating team and the patient will both be&#xD;
      blinded during the procedure. Facial nerve function and hearing will be assessed prior and&#xD;
      three months after surgery.&#xD;
&#xD;
      Outcome variables: Serviceable or non-serviceable hearing according to Gardner-Robertson&#xD;
      hearing scale and House-Brackmann score for the assessment of facial nerve function&#xD;
&#xD;
      Statistical analysis: For the evaluation of the postoperative function of the&#xD;
      vestibulocochlear nerve, the number of patients with postoperative serviceable hearing&#xD;
      (Gardner-Robertson I-II) and postoperative non-serviceable hearing (Gardner-Robertson III-V)&#xD;
      will be compared between both groups. For the evaluation of the facial nerve function, the&#xD;
      number of patients with favorable postoperative outcome (House-Brackmann I-III) and&#xD;
      non-favorable postoperative outcome (House-Brackmann IV-VI) will be compared. In both cases,&#xD;
      fisher's exact test will be used.&#xD;
&#xD;
      Expected risks/inconveniences: Administration of nimodipine is associated with the following&#xD;
      adverse effects: thrombocytopenia, allergic reactions, headache, tachycardia, hypotension,&#xD;
      nausea (occasionally) and bradycardia, ileus, reversibly elevated liver enzymes (seldom)&#xD;
&#xD;
      Risk/benefit assessment: Expected adverse effects of local nimodipine administration are&#xD;
      manageable and patients may profit from the use of nimodipine. No severe adverse events are&#xD;
      expected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">April 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 9, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Facial nerve function</measure>
    <time_frame>90 days after surgery</time_frame>
    <description>Function of the facial nerve according to House-Brackmann score. The House Brackmann score includes values from 1 to 6: 1 = normal function, 2 = minimal paresis, 3 = noticable paresis, 4 = severe paresis, 5 = minimum fuction, 6 = complete paralysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hearing</measure>
    <time_frame>90 days after surgery</time_frame>
    <description>Serviceable or non-serviceable hearing according to Gardner-Robertson scale. The Gardner-Robertson scale indludes values from 1 to 5: 1 and 2 indicating serviceable hearing, 3-5 indicating non-serviceable hearing. The scores from 1 to 5 differ in values of pure tone audiometry and speech discrimination, 1 indicates best function and 5 worst function.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vestibular Schwannoma</condition>
  <arm_group>
    <arm_group_label>Nimodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During surgery a nimodipine soaked gel foam pad is administered to the cranial nerves VII and VIII</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During surgery a sodium chloride soaked gel foam pad is administered to the cranial nerves VII and VIII</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NiMODipine Injectable Solution</intervention_name>
    <description>nimodipine solution is applied to cranial nerves during resection of vestibular schwannoma</description>
    <arm_group_label>Nimodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium chloride solution is applied to cranial nerves during surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18a&#xD;
&#xD;
          -  Vestibular schwannoma with maximum diameter of 10-25mm on MRI&#xD;
&#xD;
          -  Pre-operative audiogram&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for nimodipine application&#xD;
&#xD;
          -  Vestibularis schwannoma diameter &lt;10mm or &gt;25mm on MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorian Hirschmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic of Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Roessler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic of Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorian Hirschmann, Dr</last_name>
    <phone>+434040025780</phone>
    <email>dorian.hirschmann@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorian Hirschmann, MD</last_name>
      <phone>+4314040025780</phone>
      <email>dorian.hirschmann@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Arthur Hosmann, MD</last_name>
      <phone>+4314040025780</phone>
      <email>arthur.hosmann@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Dorian Hirschmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karl Roessler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabian Winter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Strasser, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur Hosmann</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 13, 2021</study_first_submitted>
  <study_first_submitted_qc>March 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dorian Hirschmann</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

